Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Stats
Total: 128 #1
CompanyArbutus Biopharma Corporation
Market Cap85.27MEPS (ttm)-1.79
P/E-EPS this Y35.00%
Forward P/E-EPS next Y-8.40%
PEG-EPS past 5Y-5.70%
P/S18.54EPS next 5Y-
P/B2.57EPS Q/Q-
Dividend-Sales Q/Q-41.70%
Insider Own40.87%Inst Own37.10%
Insider Trans0.00%Inst Trans-0.63%
Short Float3.96%EarningsNov 06/b
Analyst Recom1.90Target Price9.32
Avg Volume464.39K52W Range0.82 - 5.66
Nov-06-19 09:35AMArbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates Zacks
Nov-06-19 07:30AMArbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-03-19 07:13AMWe're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate Simply Wall St.
Oct-30-19 10:33AMWill Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-30-19 07:30AMArbutus to Report Third Quarter 2019 Financial Results GlobeNewswire
Oct-10-19 02:59PMBucks biopharm firm halts study of potential hepatitis B cure American City Business Journals
Oct-04-19 07:32AMThe Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering Benzinga
Oct-03-19 04:05PMArbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B GlobeNewswire
Sep-26-19 07:30AMArbutus to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-19-19 06:17AMDid You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop? Simply Wall St.
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. The company develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer AB-452, an orally administered agent, in pre-clinical studies in destabilizing HBV RNA, which leads to RNA degradation and to reduction in HBsAg levels. In addition, it engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with SOC therapies, and in combination with each other. The company has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Acuitas Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Monsanto Company; Marina Biotech, Inc.; and Arcturus Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murray Mark J.DirectorNov 28Option Exercise1.3525,00033,750341,396Nov 30 04:55 PM
CompanyAchieve Life Sciences, Inc.
Market Cap9.61MEPS (ttm)-2.64
P/E-EPS this Y83.60%
Forward P/E-EPS next Y14.90%
PEG-EPS past 5Y56.70%
P/S-EPS next 5Y-
P/B0.76EPS Q/Q72.30%
Dividend-Sales Q/Q-
Insider Own2.70%Inst Own34.90%
Insider Trans-Inst Trans-1.08%
Short Float2.73%EarningsNov 06/b
Analyst Recom1.50Target Price13.00
Avg Volume106.65K52W Range1.04 - 4.63
Nov-06-19 06:30AMAchieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program PR Newswire
Oct-31-19 05:30AMAchieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019 CNW Group
Oct-24-19 07:11AMWhat Type Of Shareholder Owns Achieve Life Sciences, Inc.'s (NASDAQ:ACHV)? Simply Wall St.
Oct-24-19 05:30AMAchieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference PR Newswire
Sep-30-19 05:30AMAchieve Life Sciences Announces Completion of Maximum Tolerated Dose Study PR Newswire
Sep-25-19 06:30AMACHV: Post Phase II Investor Day Zacks Small Cap Research
Sep-13-19 05:30AMAchieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference PR Newswire
Sep-09-19 10:34AMWhat Kind Of Share Price Volatility Should You Expect For Achieve Life Sciences, Inc. (NASDAQ:ACHV)? Simply Wall St.
Sep-05-19 05:30AMAchieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial PR Newswire
Sep-04-19 05:30AMAchieve Life Sciences Announces Presentations at Upcoming Investor Conferences PR Newswire
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol; and a strategic collaboration with National Institutes of Health for the development of cytisinicline for smoking cessation. The company is based in Vancouver, Canada.
CompanyAdaptimmune Therapeutics plc
CountryUnited Kingdom
Market Cap105.99MEPS (ttm)-0.95
P/E-EPS this Y-23.00%
Forward P/E-EPS next Y16.30%
PEG-EPS past 5Y-56.20%
P/S2.50EPS next 5Y1.00%
P/B0.62EPS Q/Q15.80%
Dividend-Sales Q/Q-97.80%
Insider Own0.22%Inst Own72.10%
Insider Trans-4.89%Inst Trans0.00%
Short Float26.34%EarningsNov 06/b
Analyst Recom2.40Target Price5.25
Avg Volume323.23K52W Range0.83 - 8.04
Nov-06-19 07:30AMAdaptimmune Reports Third Quarter 2019 Financial Results and Business Update GlobeNewswire
Nov-01-19 08:00AMAdaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019 GlobeNewswire
Oct-31-19 01:52PMIs Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds Insider Monkey
Oct-31-19 06:09AMDo Directors Own Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares? Simply Wall St.
Oct-09-19 08:00AMAdaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmunes Cell Therapies GlobeNewswire
Oct-01-19 08:00AMAdaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer GlobeNewswire
Sep-30-19 08:45AMClear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO GlobeNewswire
Sep-16-19 06:41AMDoes The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Share Price Fall With The Market? Simply Wall St.
Sep-10-19 09:01AMAdaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy Zacks
Sep-09-19 08:00AMUnited States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 GlobeNewswire
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Amado RafaelPresident, R&DAug 06Sale2.0611,04322,74917,237Aug 07 09:00 PM
Noble JamesChief Executive OfficerMay 16Option Exercise0.141,773,100253,5531,773,100May 17 06:00 PM
Bertrand William C JRChief Operating OfficerJan 14Sale5.372,27112,1943,731Jan 16 09:31 PM
Binder-Scholl Gwendolyn KnowltChief Technology OfficerJan 14Sale5.371,5148,1292,487Jan 16 09:31 PM
Rawcliffe AdrianChief Financial OfficerJan 14Sale5.373,08416,5593,318Jan 16 09:30 PM
TickerAES [NYSE, S&P 500]
CompanyThe AES Corporation
IndustryElectric Utilities
Market Cap11.41BEPS (ttm)0.62
P/E27.82EPS this Y316.90%
Forward P/E11.95EPS next Y7.79%
PEG3.09EPS past 5Y32.30%
P/S1.08EPS next 5Y9.00%
P/B3.56EPS Q/Q-83.40%
Dividend3.20%Sales Q/Q-2.10%
Insider Own0.20%Inst Own96.20%
Insider Trans208.07%Inst Trans-0.13%
Short Float1.53%EarningsNov 06/b
Analyst Recom2.40Target Price18.50
Avg Volume4.82M52W Range13.55 - 18.52
Nov-06-19 07:30AMAES (AES) Q3 Earnings Beat Estimates Zacks
Nov-06-19 06:00AMAES Delivers Strong Third Quarter Results and Accelerates Strategic Plans Business Wire
Nov-06-19 05:45AMAES and Google Create Strategic Alliance to Accelerate the Future of Energy Business Wire
Nov-05-19 10:23AMNRG Energy (NRG) to Post Q3 Earnings: What's in the Cards? Zacks
Nov-05-19 09:56AMBrookfield Infrastructure (BIP) to Post Q3 Earnings: What's Up? Zacks
Nov-05-19 08:51AMShould You Buy AES Corp (AES) Ahead of Earnings? Zacks
Nov-04-19 08:55AMDP&Ls Gift of Power Helps Local Families Stay Warm This Winter Business Wire
Nov-01-19 09:57AMAES Corp (AES) to Post Q3 Earnings: What's in the Cards? Zacks
Oct-31-19 05:50PMAES (AES) Dips More Than Broader Markets: What You Should Know Zacks
Oct-31-19 06:28AMThe AES (NYSE:AES) Share Price Is Up 50% And Shareholders Are Holding On Simply Wall St.
The AES Corporation operates as a diversified power generation and utility company. It owns and/or operates power plants to generate and sell power to customers, such as utilities, industrial users, and other intermediaries. The company also owns and/or operates utilities to generate or purchase, distribute, transmit, and sell electricity to end-user customers in the residential, commercial, industrial, and governmental sectors; and generates and sells electricity on the wholesale market. It uses a range of fuels to generate electricity, including natural gas, coal, pet coke, diesel, and oil, as well as renewables, such as hydro, solar, wind, energy storage, biomass, and landfill gas. The company owns and/or operates a generation portfolio of approximately 31,792 megawatts. It has operations in the United States, El Salvador, Chile, Colombia, Argentina, Brazil, Mexico, Central America, the Caribbean, Europe, and Asia. The company was formerly known as Applied Energy Services, Inc. and changed its name to The AES Corporation in April 2000. The AES Corporation was founded in 1981 and is headquartered in Arlington, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nebreda JulianSVP, Andes SBU PresidentAug 30Option Exercise12.1812,864156,68448,178Sep 04 04:03 PM
Nebreda JulianSVP, Andes SBU PresidentAug 30Sale15.2418,864287,54735,314Sep 04 04:03 PM
UBBEN JEFFREY WDirectorAug 12Buy15.25200,0003,050,0004,346,500Aug 14 05:24 PM
UBBEN JEFFREY WDirectorMay 13Buy15.96100,0001,596,0004,146,500May 13 05:32 PM
Gluski AndresPresident and CEOMay 09Option Exercise12.1865,000791,7001,369,839May 13 04:24 PM
TickerAGM [NYSE]
CompanyFederal Agricultural Mortgage Corporation
IndustryCredit Services
Market Cap894.46MEPS (ttm)8.94
P/E9.77EPS this Y31.20%
Forward P/E9.28EPS next Y9.80%
PEG0.89EPS past 5Y6.60%
P/S1.47EPS next 5Y11.00%
P/B1.71EPS Q/Q7.20%
Dividend3.21%Sales Q/Q21.70%
Insider Own0.10%Inst Own72.80%
Insider Trans-7.25%Inst Trans-1.05%
Short Float1.22%EarningsNov 06/b
Analyst Recom2.00Target Price85.50
Avg Volume43.39K52W Range55.64 - 88.46
Nov-06-19 08:00AMFarmer Mac Reports Third Quarter 2019 Results PR Newswire
Oct-30-19 04:15PMFarmer Mac to Announce Third Quarter 2019 Financial Results PR Newswire
Oct-25-19 06:55AMOne Thing To Remember About The Federal Agricultural Mortgage Corporation (NYSE:AGM) Share Price Simply Wall St.
Sep-29-19 08:31AMFederal Agricultural Mortgage (NYSE:AGM) Shareholders Have Enjoyed An Impressive 154% Share Price Gain Simply Wall St.
Sep-18-19 04:15PMFarmer Mac to Present at the Sidoti & Company Fall 2019 Investor Conference PR Newswire
Sep-03-19 08:57AMWhat Kind Of Investor Owns Most Of Federal Agricultural Mortgage Corporation (NYSE:AGM)? Simply Wall St.
Aug-27-19 01:59AMEdited Transcript of AGM earnings conference call or presentation 1-Aug-19 3:00pm GMT Thomson Reuters StreetEvents
Aug-08-19 07:57AMNeed To Know: Federal Agricultural Mortgage Corporation (NYSE:AGM) Insiders Have Been Selling Shares Simply Wall St.
Aug-07-19 04:15PMFarmer Mac Declares Quarterly Dividends on Common and Preferred Stock PR Newswire
Aug-01-19 05:23PMFederal Agricultural Mortgage Corp (AGM) Q2 2019 Earnings Call Transcript Motley Fool
Federal Agricultural Mortgage Corporation provides a secondary market for various loans made to borrowers in the United States. It operates through four segments: Farm & Ranch, USDA Guarantees, Rural Utilities, and Institutional Credit. The Farm & Ranch segment purchases and retains eligible mortgage loans that are secured by first liens on agricultural real estate; securitizes eligible mortgage loans, and guarantees the timely payment of principal and interest on securities representing interests in or obligations secured by pools of mortgage loans; and issues long-term standby purchase commitments (LTSPC) on designated eligible mortgage loans. The USDA Guarantees segment purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the United States Department of Agriculture (USDA). The Rural Utilities segment purchases and guarantees securities that are backed by eligible rural utilities loans; and issues LTSPCs for pools of eligible rural utilities loans. The Institutional Credit segment engages in purchasing and guaranteeing general obligations of lenders that are secured by pools of loans eligible under the Farm & Ranch, USDA Guarantees, or Rural Utilities lines of business. Federal Agricultural Mortgage Corporation was founded in 1987 and is headquartered in Washington, District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Engebretsen James RDirectorSep 04Sale79.9750039,9865,465Sep 06 04:17 PM
Faivre-Davis Sara LouiseDirectorAug 19Sale79.5730023,8714,278Aug 20 04:43 PM
NORDHOLM BRADFORD TPresident and CEOMar 22Buy69.675,000348,33115,950Mar 26 04:49 PM
Culver Chester JDirectorFeb 22Sale75.001,00075,0002,496Feb 22 04:05 PM
Hill Thomas WilliamDirectorDec 07Buy62.001509,3005,103Dec 07 04:20 PM
TickerAHC [NYSE]
CompanyA.H. Belo Corporation
IndustryPublishing - Newspapers
Market Cap77.63MEPS (ttm)0.61
P/E5.98EPS this Y-140.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-39.90%
P/S0.40EPS next 5Y-
P/B0.97EPS Q/Q-
Dividend8.85%Sales Q/Q-6.80%
Insider Own1.70%Inst Own70.10%
Insider Trans-9.89%Inst Trans-0.18%
Short Float0.07%EarningsNov 06/b
Analyst Recom-Target Price3.00
Avg Volume13.18K52W Range3.35 - 4.68
Nov-05-19 05:28PMA. H. Belo Corporation Announces Postponement of Third Quarter 2019 Financial Results Release and Conference Call GlobeNewswire
Oct-23-19 04:30PMA. H. Belo Corporation Announces Schedule for Third Quarter 2019 Financial Results Release and Conference Call GlobeNewswire
Oct-18-19 06:35AMDid You Manage To Avoid A.H. Belo's (NYSE:AHC) Painful 68% Share Price Drop? Simply Wall St.
Sep-12-19 04:30PMA. H. Belo Corporation Announces Fourth Quarter 2019 Dividend GlobeNewswire
Sep-12-19 06:27AMWhy A.H. Belo Corporation (NYSE:AHC) Looks Like A Quality Company Simply Wall St.
Aug-07-19 10:26AMHow Does A.H. Belo Corporation (NYSE:AHC) Fare As A Dividend Stock? Simply Wall St.
Aug-05-19 07:00AMThe Dallas Morning News pours more Fuel into esports coverage firestorm PR Newswire
Jul-31-19 02:39PMEdited Transcript of AHC.N earnings conference call or presentation 30-Jul-19 2:00pm GMT Thomson Reuters StreetEvents
Jul-29-19 04:15PMA. H. Belo Corporation Announces Second Quarter 2019 Financial Results GlobeNewswire
Jul-18-19 04:30PMA. H. Belo Corporation Announces Schedule for Second Quarter 2019 Financial Results Release and Conference Call GlobeNewswire
A.H. Belo Corporation, together with its subsidiaries, operates as a local news and information publishing company primarily in Texas. The company operates through two segments, Publishing and Marketing Services. The Publishing segment publishes The Dallas Morning News, a newspaper; Briefing newspaper; and Al Dia, a Spanish-language newspaper, as well as operates related Websites and applications. It also provides commercial printing, distribution, direct mail, and event-based services; and automotive classifieds on the platform. The Marketing Services Segment offers digital marketing services, such as multi-channel marketing solutions through subscription sales of its cloud-based software; marketing analytics, search engine marketing, and other marketing related services; social media account management and content marketing services; and multi-channel advertising campaigns, as well as marketing and promotional products for businesses. A.H. Belo Corporation was founded in 1842 and is headquartered in Dallas, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BECKERT JOHN ADirectorMay 21Buy3.905,00019,50040,640May 21 04:26 PM
MORONEY JAMES M IIIDirectorMay 15Sale4.012,0008,020229,164May 16 04:48 PM
MORONEY JAMES M IIIDirectorMay 14Sale4.015,00020,050231,164May 14 06:11 PM
MORONEY JAMES M IIIDirectorMay 13Sale4.0322,25689,692236,164May 14 06:11 PM
MORONEY JAMES M IIIDirectorMay 10Sale4.019,80039,298258,420May 10 05:45 PM
CompanyAlbireo Pharma, Inc.
Market Cap245.39MEPS (ttm)-5.23
P/E-EPS this Y-26.20%
Forward P/E-EPS next Y-2.20%
PEG-EPS past 5Y27.60%
P/S94.38EPS next 5Y-
P/B2.13EPS Q/Q-10.00%
Dividend-Sales Q/Q85.70%
Insider Own12.29%Inst Own82.20%
Insider Trans0.00%Inst Trans1.10%
Short Float6.87%EarningsNov 06/b
Analyst Recom1.50Target Price55.14
Avg Volume53.50K52W Range16.13 - 38.69
Nov-06-19 07:30AMAlbireo Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Nov-04-19 08:30AMAlbireo Appoints Michelle Graham as Chief Human Resources Officer GlobeNewswire
Nov-02-19 09:26AMWill Albireo Pharma (NASDAQ:ALBO) Spend Its Cash Wisely? Simply Wall St.
Nov-01-19 08:30PMPrimo Water, Verso, Arch Coal and Other 13D Filings
Oct-30-19 08:00AMAlbireo to Report Third Quarter 2019 Financial Results on November 6, 2019 GlobeNewswire
Oct-03-19 08:00AMAlbireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families GlobeNewswire
Sep-30-19 09:23AMAlbireo Announces Presentations at NASPGHAN 2019 Annual Meeting GlobeNewswire
Sep-18-19 06:05AMIs Albireo Pharma, Inc. (NASDAQ:ALBO) A Volatile Stock? Simply Wall St.
Sep-03-19 08:30AMAlbireo to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-09-19 03:23AMAlbireo Pharma, Inc. (ALBO) Q2 2019 Earnings Call Transcript Motley Fool
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cooper Ronald Harold WilfredPresident and CEONov 13Buy25.021,02625,6687,760Nov 15 04:12 PM
TickerALE [NYSE]
CompanyALLETE, Inc.
IndustryDiversified Utilities
Market Cap4.33BEPS (ttm)4.08
P/E20.53EPS this Y8.30%
Forward P/E22.03EPS next Y7.43%
PEG2.93EPS past 5Y5.10%
P/S2.99EPS next 5Y7.00%
P/B1.96EPS Q/Q42.50%
Dividend2.80%Sales Q/Q-15.60%
Insider Own0.30%Inst Own72.30%
Insider Trans-14.20%Inst Trans-0.16%
Short Float1.10%EarningsNov 06/b
Analyst Recom3.00Target Price86.20
Avg Volume204.36K52W Range72.42 - 88.60
Nov-06-19 07:55AMAllete (ALE) Q3 Earnings and Revenues Miss Estimates Zacks
Nov-06-19 06:30AMALLETE, Inc. Reports Third Quarter 2019 Earnings Business Wire
Nov-01-19 12:00PMMinnesota Power Files Rate Request and Asks State Regulators to Increase Its Annual Operating Revenue Business Wire
Nov-01-19 11:37AMSuperior Water, Light and Power Company -- Moody's announces completion of a periodic review of ratings of ALLETE, Inc. Moody's
Oct-30-19 10:34AMEarnings Preview: Allete (ALE) Q3 Earnings Expected to Decline Zacks
Oct-28-19 06:30AMHere's How P/E Ratios Can Help Us Understand ALLETE, Inc. (NYSE:ALE) Simply Wall St.
Oct-24-19 10:52AMHedge Funds Have Never Been This Bullish On ALLETE Inc (ALE) Insider Monkey
Oct-24-19 06:30AMALLETE Board of Directors Declares Dividend on Common Stock Business Wire
Oct-11-19 06:07AMWith A Return On Equity Of 8.9%, Has ALLETE, Inc.'s (NYSE:ALE) Management Done Well? Simply Wall St.
Oct-03-19 06:30AMALLETE to Announce Third Quarter Financial Results on November 6 Business Wire
ALLETE, Inc. operates as an energy company. The company operates through three segments: Regulated Operations, ALLETE Clean Energy, and U.S. Water Services. It generates electricity from coal-fired, wind, hydroelectric, natural gas-fired, biomass co-fired, solar, and other sources. The company provides regulated utility electric, natural gas, and water services in northwestern Wisconsin to approximately 15,000 electric customers, 13,000 natural gas customers, and 10,000 water customers, as well as regulated utility electric services in northeastern Minnesota to approximately 145,000 retail customers and 16 non-affiliated municipal customers. It also owns and maintains electric transmission assets in Wisconsin, Michigan, Minnesota, and Illinois. In addition, the company focuses on developing, acquiring, and operating clean and renewable energy projects; and owns and operates approximately 545 megawatt of wind energy generation. Further, it offers integrated water management for industry by combining chemical, equipment, engineering, and service for customized solutions to reduce water and energy usage. Additionally, the company is involved in the coal mining operations in North Dakota; and real estate investment activities in Florida. The company owns and operates 159 substations with a total capacity of 8,531 megavolt amperes. It serves taconite mining, iron concentrate, paper, pulp and wood products, pipeline, and other industries. The company was founded in 1906 and is headquartered in Duluth, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hodnik Alan RChairman & CEOSep 12Sale86.986,000521,88061,675Sep 13 02:52 PM
Hodnik Alan RChairman & CEOAug 07Sale85.096,000510,54067,377Aug 08 02:29 PM
Hodnik Alan RChairman & CEOJun 12Sale84.744,000338,96073,377Jun 13 02:51 PM
DINDO KATHRYN WDirectorMay 21Sale82.0373560,29215,146May 22 04:21 PM
Hodnik Alan RChairman & CEOMay 21Sale82.244,000328,96076,854May 22 03:06 PM
CompanyAmplify Energy Corp.
IndustryIndependent Oil & Gas
Market Cap295.20MEPS (ttm)-0.77
P/E-EPS this Y156.40%
Forward P/E2.38EPS next Y-0.31%
PEG-EPS past 5Y15.30%
P/S1.79EPS next 5Y15.00%
P/B0.36EPS Q/Q-
Dividend10.50%Sales Q/Q-71.70%
Insider Own8.47%Inst Own76.80%
Insider Trans-Inst Trans52.20%
Short Float2.05%EarningsNov 06/b
Analyst Recom-Target Price14.00
Avg Volume279.55K52W Range4.01 - 13.23
Nov-06-19 07:00AMAmplify Energy Announces Third Quarter 2019 Results, Fourth Quarter 2019 Dividend, Merger Integration Update and Fourth Quarter 2019 Guidance GlobeNewswire
Oct-23-19 05:00PMAmplify Energy Announces Third Quarter 2019 Earnings Release Date GlobeNewswire
Oct-23-19 01:08PMThese Were The Companies Added And Removed From OTC Markets Indexes At The End Of Q3 Benzinga
Oct-14-19 06:27AMAmplify Energy (NYSE:AMPY) Takes On Some Risk With Its Use Of Debt Simply Wall St.
Sep-11-19 05:00PMAmplify Energy to Participate in the 2019 Johnson Rice Energy Conference GlobeNewswire
Aug-14-19 03:34PMWhat Can We Make Of Amplify Energy Corp.s (NYSE:AMPY) High Return On Capital? Simply Wall St.
Aug-06-19 09:00AMAmplify Energy Announces Closing of Merger with Midstates, Guidance for Second Half 2019, Recurring Dividend with Current Yield of 18% and Share Buyback Plan GlobeNewswire
Aug-05-19 07:00AMAmplify Energy Announces Second Quarter 2019 Results and Midstates Merger Update GlobeNewswire
Aug-02-19 04:30PMAmplify Energy Announces Shareholder Approval of Merger with Midstates GlobeNewswire
Jul-29-19 05:00PMAmplify Energy Announces Second Quarter 2019 Earnings Release Date GlobeNewswire
Amplify Energy Corp. engages in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's properties consist of operated and non-operated working interests in producing and undeveloped leasehold acreage, as well as working interests in identified producing wells located in the Rockies, federal waters offshore Southern California, East Texas/North Louisiana, and South Texas. As of December 31, 2018, it had total estimated proved reserves of approximately 841.1 billion cubic feet of natural gas equivalent; and 2,068 gross wells. The company was formerly known as Memorial Production Partners LP and changed its name to Amplify Energy Corp. in May 2017. Amplify Energy Corp. was founded in 2011 and is based in Houston, Texas.
CompanyAmneal Pharmaceuticals, Inc.
IndustryDrugs - Generic
Market Cap923.88MEPS (ttm)-0.52
P/E-EPS this Y97.50%
Forward P/E4.80EPS next Y35.80%
PEG-EPS past 5Y-16.10%
P/S0.51EPS next 5Y10.40%
P/B0.96EPS Q/Q12.10%
Dividend-Sales Q/Q-2.20%
Insider Own0.70%Inst Own84.80%
Insider Trans-Inst Trans3.27%
Short Float6.46%EarningsNov 06/b
Analyst Recom2.50Target Price4.71
Avg Volume1.70M52W Range2.27 - 21.22
Nov-06-19 09:45AMAmneal Pharmaceuticals (AMRX) Lags Q3 Earnings and Revenue Estimates Zacks
Nov-06-19 06:32AMAmneal Reports Third Quarter 2019 Financial Results Business Wire
Nov-06-19 06:30AMAmneal Enters into a Licensing Agreement with Kashiv BioSciences, LLC to Develop and Commercialize K127 for the Treatment of Myasthenia Gravis Business Wire
Oct-30-19 10:34AMEarnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline Zacks
Oct-21-19 10:01AMIs Amneal Pharmaceuticals, Inc. (AMRX) Going To Burn These Hedge Funds ? Insider Monkey
Oct-11-19 01:50PMSome Amneal Pharmaceuticals (NYSE:AMRX) Shareholders Have Taken A Painful 85% Share Price Drop Simply Wall St.
Oct-10-19 09:25AMAmneal Announces Launch of Generic Invega® Business Wire
Oct-09-19 08:30AMAmneal to Report Third Quarter 2019 Results on November 6, 2019 Business Wire
Aug-22-19 12:16PMAmneal Pharmaceuticals, Inc. (AMRX) Q2 2019 Earnings  Call Transcript Motley Fool
Aug-09-19 04:09PMLargest Insider Trades of the Week
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
1 2 3 4 5 6 ... 10 ... 13 next